ONM 400 IL-2
Alternative Names: ONM-400-IL-2Latest Information Update: 28 Jul 2024
At a glance
- Originator OncoNano Medicine
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 13 Nov 2020 Pharmacokinetics and pharmacodynamics results from preclinical studies in Solid tumours presented at the Society for Immunotherapy of Cancer Annual Meeting (SITC-2020)
- 22 Jul 2020 Pharmacokinetics data from a preclinical studies in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)